Find Clinical Trial

An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.


← Back
Study Phase

Phase 2

Therapeutic Area

Immune-Inflammatory Diseases

IndicationSchnitzler syndrome
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

GEVOKIZUMAB,
S078989

Active Substance CodeS078989
Protocol CodeCL2-78989-018
EudraCT Code2013-002562-39


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility